|
Monday, 08/02/2010
|
In Vitro Drug Combination Analysis in Excel: A Case Study in HIV
Karen Chiswell, GlaxoSmithKline; Katja Sabine Remlinger, GlaxoSmithKline; Mark Underwood, GlaxoSmithKline
|
Combining Molecularly Targeted Agents in Cancer Therapy
Eunice Kwak, Massachusetts General Hospital Cancer Center
8:35 AM
|
A Conditional Bayesian Logistic Regression Model (BLRM) with Overdose Control
Lu-May Chiang, Novartis Pharmaceuticals Corporation; Adarsh Joshi, Eli Lilly and Company; David Ohlssen, Novartis Pharmaceuticals Corporation; Jyotirmoy Dey, Novartis Pharmaceuticals Corporation
9:05 AM
|
Adaptive Factorial Designs for Combination Therapy in Oncology
Donald Arthur Berry, MD Anderson Cancer Center
9:15 AM
|
Estimating Incremental Value in Marker Combinations Using a Two-Stage Study Design
Aasthaa Bansal, University of Washington; Margaret Sullivan Pepe, Fred Hutchinson Cancer Research Center
3:35 PM
|
|
Tuesday, 08/03/2010
|
Impact of Relying on Sample Variance-Covariance Estimate on Prediction Accuracy and Statistical Power of Hypothesis Testing When n << p
Peter H. Hu, Merck & Co., Inc.; Yue Wang, Merck & Co., Inc.; Jared Lunceford, Merck & Co., Inc.
|
Combination of Confidence Distributions (CDs) and an Efficient Approach for Meta-Analysis of Heterogeneous Studies
Dungang Liu, Rutgers University; Regina Liu, Rutgers University; Minge Xie, Rutgers University
8:50 AM
|
Interval Estimation in Two-Stage, Drop-the-Losers Clinical Trials with Flexible Treatment Selection
Dan Neal, University of Florida; George Casella, University of Florida; Mark Yang, University of Florida; Samuel S. Wu, University of Florida
3:05 PM
|
|
Wednesday, 08/04/2010
|
Minimum Quantile Distance Estimation of Quantiles Using Linear Combinations of Standard Quantile Functions as Models
Dean H. Fearn , California State University, East Bay; Elliott Nebenzahl, California State University, East Bay
|
Comparisons of Estimators of Process Standard Deviation in Constructing Shewhart Control Charts with Unequal Subgroup Sizes
Nien Fan Zhang, National Institute of Standards and Technology; Per Winkel, Copenhagen Trial Unit
9:05 AM
|
A Bayesian Design for a Proof-of-Concept Study Comparing Rituxan in Combination with a New Drug to Rituxan Alone
Sharon C. Murray, GlaxoSmithKline; John F. Toso, GlaxoSmithKline; John W. Bauman, GlaxoSmithKline;
11:15 AM
|
|